IMVEXXY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IMVEXXY (IMVEXXY).
Estradiol, a form of estrogen, binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and producing effects such as proliferation of the vaginal epithelium and increased cervical secretions, which relieve vulvar and vaginal atrophy symptoms.
| Metabolism | Estradiol is primarily metabolized in the liver via conversion to estrone and estriol, which are further metabolized via hydroxylation, glucuronidation, and sulfation. Key enzymes include CYP450 isoforms (e.g., CYP1A2, CYP3A4) and UDP-glucuronosyltransferases (UGTs). |
| Excretion | Primarily renal as glucuronide conjugates; approximately 30-50% of a dose is excreted in urine as estradiol metabolites, with ~10% excreted in feces via biliary elimination. |
| Half-life | Terminal elimination half-life of estradiol is approximately 13-14 hours (range 10-16 hours) after vaginal administration, supporting once-daily dosing. |
| Protein binding | Estradiol is approximately 98% bound to serum proteins, mainly sex hormone-binding globulin (SHBG, ~40%) and albumin (~58%). |
| Volume of Distribution | Apparent volume of distribution of estradiol is approximately 1.7 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Bioavailability after vaginal administration is approximately 5-10% relative to oral administration due to first-pass hepatic metabolism; peak concentrations are lower than oral but more consistent. |
| Onset of Action | Systemic estradiol levels peak within 1-4 hours after vaginal administration; clinical effect on vasomotor symptoms may be noted within 2-4 weeks. |
| Duration of Action | Duration of action for systemic effects is approximately 24 hours with daily dosing; for local effects (vaginal atrophy), therapeutic benefit persists with continued use. |
| Molecular Weight | 312.45 |
IMVEXXY (estradiol vaginal insert) 10 mcg inserted vaginally once daily for 2 weeks, then twice weekly (e.g., Monday and Thursday).
| Dosage form | INSERT |
| Renal impairment | No dose adjustment required for renal impairment; pharmacokinetics not studied in severe renal impairment. |
| Liver impairment | Contraindicated in hepatic impairment; no specific Child-Pugh based guidelines available. |
| Pediatric use | Not indicated for pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use lowest effective dose for shortest duration due to increased risk of thromboembolism and malignancy. |
| 1st trimester | Contraindicated due to risk of fetal harm; estrogens cross placenta and may cause urogenital abnormalities. |
| 2nd trimester | Contraindicated; fetal exposure to exogenous estrogens may lead to reproductive tract anomalies. |
| 3rd trimester | Contraindicated; estrogens reported to cause vaginal adenosis in female offspring and potential for other adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for IMVEXXY (IMVEXXY).
| Placental transfer | Estradiol and estradiol acetate cross the placenta; documented transfer in humans. |
| Breastfeeding | Excreted in human milk in small amounts; may reduce milk production and quality. Use caution, especially in nursing mothers of preterm infants. |
| Lactation Rating |
■ FDA Black Box Warning
Estrogen-Alone Therapy: Endometrial cancer – The risk of endometrial cancer is increased in women with a uterus using unopposed estrogens. Add a progestin if the uterus is intact. Cardiovascular disorders and probable dementia – Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia. The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis, and the WHI Memory Study reported an increased risk of probable dementia in women 65 years of age or older.
| Serious Effects |
Undiagnosed abnormal genital bleedingKnown or suspected breast cancerKnown or suspected estrogen-dependent neoplasiaActive or past history of venous thromboembolismActive thrombophlebitisHypersensitivity to estradiol or any componentHepatic impairment or disease
| Precautions | Cardiovascular disorders (e.g., stroke, DVT), Malignant neoplasms (e.g., endometrial cancer, breast cancer), Gallbladder disease, Hypercalcemia, Visual abnormalities, Hepatic impairment, Fluid retention, Hypothyroidism, Hypertriglyceridemia, Exacerbation of endometriosis, Hereditary angioedema, Porphyria |
| Food/Dietary |
Loading safety data…
| L4 |
| Teratogenic Risk | Estrogens are not recommended for use during pregnancy. IMVEXXY (estradiol vaginal insert) is indicated for the treatment of moderate to severe dyspareunia due to menopause and has no approved use in pregnancy. Data from epidemiologic studies and meta-analyses have not found an increased risk of major birth defects after first-trimester exposure to estrogens. However, prolonged exposure to estrogens during pregnancy has been associated with an increased risk of vaginal adenosis, cervical and vaginal clear cell adenocarcinoma in female offspring, and genital tract abnormalities in male offspring. Therefore, use is contraindicated in pregnancy. |
| Fetal Monitoring | No specific maternal-fetal monitoring is required for IMVEXXY because it is not indicated for use in pregnancy. However, if inadvertent exposure occurs during pregnancy, no specific monitoring is recommended beyond routine prenatal care. |
| Fertility Effects | IMVEXXY is indicated for postmenopausal women and does not affect fertility. In premenopausal women, estradiol can affect fertility by interfering with ovulation via negative feedback on gonadotropin secretion. |
| No significant food interactions. Grapefruit juice may increase systemic estradiol levels; avoid large quantities. Estradiol may affect glucose tolerance; monitor blood sugar in diabetic patients. |
| Clinical Pearls | IMVEXXY (estradiol vaginal insert) is indicated for moderate to severe dyspareunia due to vulvar and vaginal atrophy in postmenopausal women. Use the lowest effective dose for the shortest duration. Not for use in women with undiagnosed abnormal genital bleeding, known/suspected estrogen-dependent neoplasia, or history of thromboembolic disorders. Local side effects include vaginal discharge, vulvovaginal discomfort, and spotting. Monitor for endometrial cancer risk with prolonged use; consider addition of progestin if uterus intact. |
| Patient Advice | Insert IMVEXXY once daily for 2 weeks, then twice weekly thereafter. Wash hands before and after insertion. · Do not use if you have vaginal bleeding of unknown cause, breast cancer, or blood clotting disorders. · Common side effects include vaginal discharge, burning, or irritation. Report any unusual bleeding, pain, or swelling. · Use the applicator as directed; discard each applicator after single use. · This medication may interact with warfarin; notify your healthcare provider of all medications. · Avoid using other vaginal products (creams, lubricants) at the same time unless directed by your doctor. · Do not use during pregnancy or breastfeeding. |